E-course: The role of MRI in prostate cancer screening and diagnosis
The e-course will explore the role of MRI in prostate cancer (PCa) screening and diagnosis, focusing on recent clinical trials such as Gothenburg and TRANSFORM. The experts will discuss how MRI-guided screening is transforming early detection, biopsy rates, and diagnostic accuracy.
| Organiser | European School of Urology (ESU) |
|---|---|
| CME | 1.00 |
| Duration | Approx. 60 minutes |
This is the second episode of the new UROwebinar series “Prostate Cancer Screening: PRAISE U training toolbox” organised by the European School of Urology, the EAU Policy Office, and the PRAISE-U Consortium. This e-course will begin with a brief recap of the previous episode.
The e-course will explore the role of MRI in prostate cancer (PCa) screening and diagnosis, focusing on recent clinical trials such as Gothenburg and TRANSFORM. The experts will discuss how MRI-guided screening is transforming early detection, biopsy rates, and diagnostic accuracy.
This e-course will also highlight debates on the applicability of trial findings to broader populations, as well as the potential impact on real-world screening protocols and patient outcomes.
Additionally, the e-course will examine the implications for radiologists and urologists, which will include the feasibility of MRI-first screening and its integration into clinical practice across Europe.
A dedicated lecture will focus on artificial intelligence (AI) advancements in MRI interpretation, exploring how emerging technologies may enhance PCa detection and streamline workflows.
Speakers:
- Dr. R. Van Den Bergh (NL)
- Prof. H. Van Poppel (BE)
- Dr. V. Kasivisvanathan (GB)
- Dr. J. Wallstrom (SE)
- Dr. I.G. Schoots (NL)
- Dr. A. Chandran (FR)
This e-course is brought to you in collaboration with the EAU Policy Office and the PRAISE-U Consortium.